SCIENTIFIC REPORT

Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia

C Chen¹, D Louis¹, T Dodd² and J Muecke¹

¹ Ophthalmic Oncology Unit, Department of Ophthalmology, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia
² Institute of Medicine and Veterinary Science, Frome Road, Adelaide, SA 5000, Australia

Correspondence to:
Correspondence to:
Dr James Muecke
Department of Ophthalmology, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia; raheyes{at}mail.rah.sa.gov.au

Aim: To report the outcome of topical mitomycin C (MMC) used as adjunctive treatment following primary excision of ocular surface squamous neoplasia (OSSN).

Method: Prospective, non-comparative interventional case series of 27 primary OSSN lesions from 26 patients treated in a single ocular oncology centre over a 4 year period.

Result: 27 cases of OSSN received a treatment regimen of surgical excision, followed by topical MMC. Mean follow up of 27 (SD 12) months (range 12–50, median 25 months) revealed zero recurrences.

Conclusion: MMC treatment following surgical excision decreases the recurrence rate of primary ocular surface neoplasia and should be considered as adjunctive therapy in primary treatment.

Keywords: mitomycin C; ocular surface squamous neoplasia; surgery

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Granada, J. F., Ensenat, D., Keswani, A. N., Kaluza, G. L., Raizner, A. E., Liu, X.-m., Peyton, K. J., Azam, M. A., Wang, H., Durante, W. (2005). Single Perivascular Delivery of Mitomycin C Stimulates p21 Expression and Inhibits Neointima Formation in Rat Arteries. Arterioscler. Thromb. Vasc. Bio. 25: 2343-2348 [Abstract] [Full Text]